Sunwin ( SUWN ) explodiert !
Seite 96 von 102 Neuester Beitrag: 25.04.21 03:17 | ||||
Eröffnet am: | 24.01.06 12:38 | von: gameznman | Anzahl Beiträge: | 3.526 |
Neuester Beitrag: | 25.04.21 03:17 | von: Brigitteojnfa | Leser gesamt: | 532.696 |
Forum: | Hot-Stocks | Leser heute: | 2 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 93 | 94 | 95 | | 97 | 98 | 99 | ... 102 > |
We sell stevioside, a natural sweetener, as well as veterinary products
and herbs used in traditional Chinese medicine. Substantially all of our
operations are located in the People's Republic of China (PRC). As an industry
leader in agricultural processing, we have built an integrated firm with the
sourcing and production capabilities to meet the needs of our customers. The
Sunwin family works closely with consumers to provide quality, value, and a
hybrid mix of agricultural products and services that meet growing demand.
Our operations are organized into two operating segments related to our
product lines:
o Stevioside - a natural sweetener, and
o Veterinary medicines and traditional Chinese medicine formula
extracts.
The products manufactured and sold by these operating groups are as
follows.
Nirgentwo steht was von rübenzucker,ich such noch was anderes raus
The Shandong Province is a primary harvesting base of stevia leaves as
well as the main region for the production of stevioside in China. Prior to
fiscal 2007 we routinely entered into harvesting contracts with local farmers to
insure sufficient supply of raw materials. In 2006, approximately 30% of our
supply of stevia came from harvesting contracts with several large plantations
in China covering approximately 277 acres used to grow stevioside rebaudiana.
Prior to fiscal 2007 we generally paid the farmers 30% of the contract price at
the time the seed is planted, generally in March of each year, and the remaining
70% upon delivery of the leaves.
In fiscal 2007, we observed that the stevia rebaudiana harvest in China
was expanding. This expansion has stabilized the market supply of stevia and we
are no longer required to prepay farmers to harvest stevia to ensure a steady
supply. Rather in fiscal 2007, we purchased all raw materials directly from the
market and paid for the leaves at the time of purchase. Currently the price of
stevia leaves is approximately $1,812 per ton, and the price of stevioside
ranges from approximately $21,000 to $29,000 per ton. In the past, in an effort
to monitor the quality of the stevia, our company set up a fine breed base so
that we could monitor the quality of stevia raw material. Under the new policy
we maintain control by testing the stevia leaves at the time of purchase. Our
internal policy is to only purchase stevia leaves with a stevioside content of
greater than12%. We believe that there is ample supply of leaves with a
stevioside content in excess of 12% available in the market.
hab übrigens mit stevia schon 4 kg abgenommen.(2kg weil ich meinen Kaffee damit süss und 2kg weil die aktie an mir zehrt.)
Der Pressesprecher von Nestlé spricht von strategischer Neuausrichtung Richtung Ernährung/Gesundheit/Wohlbefinden!
*lol*
Stevia ist doch hier ganz verboten.
Natürlich hat ein grosser mehr einfluss bei der zulassung.
Die Zulassung in der EU wird wohl in nicht mehr alzu ferner Zukunft kommen und dann werden die Karten neu gemischt.
Wer weiß was die Großen schon alles so in ihren tiefen Schubladen planen.
Nicht morgen und auch nicht übermorgen, aber langfristig wird da noch einiges passieren was sich in dieser Diskussion heute noch keiner vorstellen kann. Hinterher sagen dann wieder alle:"Das war doch klar, haben wir schon immer gewust." Nur vorher sind die Leute oft erstaunlich phantasielos. Dabei wusste doch Kostolany schon das Phantasie an der Börse wichtiger als Wissen ist!
Coca-Cola hat da ja offiziell den Startschuß für gegeben.
Was machen also jetzt die Europäer, verpennen sie diesen Trend?
Spätestens wenn in der USA die Zulassung erfolgt ist, woran ich kaum noch Zweifel mehr habe (Coca-Cola bekommt das hin!) , wird diese Welle auch nach Euopa rollen.
So blind werden Konzerne wie Nestlé und Co. nicht sein, das sie sich in diesem Mega-Geschäft die Butter vom Brot nehmen lassen, das hoffe ich zumindest.
Vielleicht gibt es dann irgendwann einen Stevia-Future und spätestens wenn der mehr Handelsvolumen hat als der Zucker-Future haben wird, werden so einige große Augen machen.
Das umfeld hier bei ariva doch sehr angenehm.
Der eine sieht es so,der andere so,siehe trading,der meint es ernst.
Hoffe nur,das die kursentwicklung ein scherz ist.
ChangeWave Alliance Report:
The rise of retail medicine signals big future for science-based nutrition
By Josh Levine
Food-as-medicine is a concept increasingly accepted -- and even embraced -- by consumers.
Due to advancements in medical science and a vast compilation of nutritional studies, the old saying "you are what you eat" is now virtually accepted as a universal truth.
Even though science-based nutrition -- including food-as-medicine -- is thought to hold great promise, growth has historically been lackluster due to a deficit of physician focus on smart nutritional habits and preventive medicine.
A recent ChangeWave Alliance survey on retail medicine indicated this may be changing, as bioactive foods, dietary supplements and nutritional counseling showed increased momentum within the healthcare industry.
I should add that these trends especially bode well for an exciting little company that we've recommended in our ChangeWave MicroCap Investor advisory service. But more of that later. Let's first look at key trends.
No one can predict the future, but at ChangeWave Investing we’ve got the next best thing -- the ChangeWave Alliance. Made up of 10,000 strategically positioned experts, the Alliance can let you in on opportunities and risks months ahead of the crowd! Click here to learn how.
Food for Thought
The business of retail medicine focuses on unique, personalized products and services that help patients manage their healthcare, but these products and services are paid for by the patients and not their insurance company. It's a robust business, according to the 279 healthcare industry respondents who participated in our most recent survey.
Seventy-six percent of our respondents who work in a medical practice, hospital or clinic said they see a trend toward retail medicine at their location. They cited nutrition and dietary products and programs as the biggest growth drivers.
Moreover, 24% reported that their medical work locales sold dietary products and services directly to their patients -- and another 14% said they plan to begin doing so in the next 12 months.
But what dietary products and services are sold currently at these practices, hospitals and clinics? And what ones will begin to be sold during the coming year?
Diet & Nutritional Products/Services Sold to Patients
Current and Future Market Share
Among those who sold dietary products and services at their practice, 70% said they sell nutritional counseling and services and 65% said they sell vitamins. Similarly, among those who said they plan to begin selling dietary products and services in the next 12 months, 55% said they will sell nutritional counseling and services, 50% said vitamins, and 50% said dietary supplements.
We noted that the strongest momentum is in bioactive foods, which increased from 14% currently to 26% of respondents who reported that their locale plans to begin selling them in the next 12 months.
Bioactive foods contain bio-molecules that modulate metabolism and treat specific conditions such as high blood glucose levels. Such foods are just beginning to come to market on a mass scale, and some analysts believe they may revolutionize how certain conditions are treated.
NXXI -- Healthy for Your Portfolio
Turning to one of our favorite microcaps -- New York-based Nutrition 21 (NXXI) is developing both dietary supplements and bioactive foods to treat specific conditions such as high blood glucose levels.
What makes Nutrition 21 stand apart from the crowd is that it's a true bioscience company -- not a run-of-the-mill reseller -- that approaches nutrition in a way similar to how pharmaceutical firms create their drugs:
* NXXI develops products based on a strong foundation of research and development and has an extensive patent portfolio that it has aggressively and successfully defended.
* The company performs numerous clinical studies with leading academic, institutional and government partners.
* NXXI proactively engages and educates the medical community about the advantages of its proprietary products.
As you can tell, I'm quite excited about the company. Importantly, Nutrition 21 relies on large-scale, double-blind, placebo-controlled, clinical trials as a key element to its marketing strategy.
This is critical to its future success, as healthcare providers are most likely to rely on FDA-approved drugs as the first choice of therapy for patients -- particularly those suffering from high-risk chronic diseases.
Today, Nutrition 21 is in the beginning stages of transforming from an ingredient supplier to a seller of branded, therapeutic products for a wide range of diseases including obesity, pre-diabetes, diabetes, cardiovascular health, and arthritis and joint health.
Its business strategy is already making an impact.
Revenues for the most recent quarter (fiscal Q3) soared more than 500% to $16.1 million, of which $13.6 million were from sales of innovative branded products like Diachrome for people with Type 2 diabetes.
Based on the above trends in retail medicine, and on sharply improving corporate fundamentals, Nutrition 21 looks well situated for a very profitable future.
bleibe bei meinem ersten posting,ein bisschen spielen mit sunwin sonst nichts.
ciao
jackomo
Es ist allerdings erst seit july in den groceries zu erhalten.
Die werbekampagne läuft in diesen tagen an.
Die firma hatte doch bekanntgegeben,das ab july monatlich 10t premiumstevia
nach südkorea verkauft werden.Mehr können sie doch nicht.
Das einzige ist wohl,einige dachten,onlysweet kommmt in den usa auf den markt,die ammis reissen es sofort aus den regalen.
Das ist wohl ein irrtum.
Der aktienkurs kommt unter die räder,ist auch fakt.
Da kommt allerdings momentan auch einiges andere unter die räder,ist nätürlich ein schwacher trost.
Es ist wie meistens,die,die überzeugt sind auf lange sicht,bleiben eh.
Mal schauen,wie die in den usa schliessen.